Have a personal or library account? Click to login
Ferritin and procalcitonin in COVID-19 associated acute kidney injury – gender disparities, but similar outcomes Cover

Ferritin and procalcitonin in COVID-19 associated acute kidney injury – gender disparities, but similar outcomes

Open Access
|Feb 2023

References

  1. 1. COVID-19 CORONAVIRUS PANDEMIC, available online: https://www.worldometers.info/coronavirus/, accessed on 21 November 2022.
  2. 2. Thakur V, Ratho RK, Kumar P, Bhatia SK, Bora I, Mohi GK, et al. Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations. J Clin Med. 2021 Jan 24;10(3):446. DOI: 10.3390/jcm10030446786618933498861
  3. 3. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 Jul;26(7):1017-32. DOI: 10.1038/s41591-020-0968-332651579
  4. 4. Fu EL, Janse RJ, de Jong Y, van der Endt VHW, Milders J, van der Willik EM, et al. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clin Kidney J. 2020 Sep 2; 13(4): 550-63. DOI: 10.1093/ckj/sfaa160746759332897278
  5. 5. Głowacka M, Lipka S, Młynarska E, Franczyk B, Rysz J. Acute Kidney Injury in COVID-19. Int J Mol Sci. 2021 Jul 28;22(15):8081. DOI: 10.3390/ijms22158081834753634360866
  6. 6. He W, Liu X, Hu B, Li D, Chen L, Li Y, et al. Gender and Ethnic Disparities of Acute Kidney Injury in COVID-19 Infected Patients: A Literature Review. Front Cell Infect Microbiol. 2022 Jan 13;11:778636. DOI: 10.3389/fcimb.2021.778636882317935145920
  7. 7. Toth-Manikowski SM, Caldwell J, Joo M, Chen J, Meza N, Bruinius J, et al; STOP-COVID Investigators. Sex-related differences in mortality, acute kidney injury, and respiratory failure among critically ill patients with COVID-19. Medicine (Baltimore). 2021 Dec 17;100(50):e28302. DOI: 10.1097/MD.0000000000028302867798934918709
  8. 8. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020 Apr 29;8:152. DOI: 10.3389/fpubh.2020.00152720110332411652
  9. 9. El Mouhayyar C, Dewald J, Cabrales J, Tighiouart H, Moraco AH, Jaber BL, et al. Factors Associated with Severity of Acute Kidney Injury and Adverse Outcomes in Critically Ill Patients with COVID-19. Nephron. 2022 Jun 8: 1-9. DOI: 10.1159/000524657939377635675790
  10. 10. Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS One. 2021 Jul 9; 16(7): e0254066. DOI: 10.1371/journal.pone.0254066827014534242273
  11. 11. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16; 181(2): 271-80.e8. DOI: 10.1016/j.cell.2020.02.052710262732142651
  12. 12. Khan S, Chen L, Yang CR, Raghuram V, Khundmiri SJ, Knepper MA. Does SARS-CoV-2 Infect the Kidney? J Am Soc Nephrol. 2020 Dec;31(12):2746-8. DOI: 10.1681/ASN.2020081229779020333051359
  13. 13. Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Jänne OA. Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol. 2010 Apr 12; 317(1-2):14-24. DOI: 10.1016/j.mce.2009.12.02220035825
  14. 14. Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1280-1. DOI: 10.1152/ajplung.00153.2020727698232432918
  15. 15. O’Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age. J Ovarian Res. 2020 Nov 24; 13(1):137. DOI: 10.1186/s13048-020-00734-4768485433234144
  16. 16. Wenzhong, L.; Hualan, L. COVID-19: Attacks the 1-beta Chain of Hemoglobin to Disrupt Respiratory Function and Escape Immunity. ChemRxiv 2022, Cambridge Open Engage, available online: doi: 10.26434/chemrxiv-2021-dtpv3-v11. DOI: 10.26434/chemrxiv-2021-dtpv3-v11
  17. 17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013, Suppl 3,1-150.
  18. 18. Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022 Feb; 67: 172-181. DOI: 10.1016/j.jcrc.2021.09.023860455734808527
  19. 19. Ahmed S, Jafri L, Hoodbhoy Z, Siddiqui I. Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review. Indian J Crit Care Med. 2021 Jan;25(1):77-84. DOI: 10.5005/jp-journals-10071-23706787429133603306
  20. 20. Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care. 2004 Feb;8(1):R12-20. DOI: 10.1186/cc239642005814975050
  21. 21. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol. 2001 Feb;18(2): 79-87. DOI: 10.1097/00003643-200102000-00004
  22. 22. Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil percentage. Int Urol Nephrol. 2017 Dec;49(12):2205-16. DOI: 10.1007/s11255-017-1710-z28956241
  23. 23. Wu SC, Liang CX, Zhang YL, Hu WP. Elevated serum procalcitonin level in patients with chronic kidney disease without infection: A case-control study. J Clin Lab Anal. 2020 Feb;34(2):e23065. DOI: 10.1002/jcla.23065703159231617251
  24. 24. Nakamura Y, Murai A, Mizunuma M, Ohta D, Kawano Y, Matsumoto N, et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury. J Infect Chemother. 2015 Apr; 21(4): 257-63. DOI: 10.1016/j.jiac.2014.12.00125677555
  25. 25. Chun K, Chung W, Kim AJ, Kim H, Ro H, Chang JH, et al. Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients. Sci Rep. 2019 Mar 18;9(1):4777. DOI: 10.1038/s41598-019-41291-1642301930886220
  26. 26. Takahashi G, Shibata S, Fukui Y, Okamura Y, Inoue Y. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis. 2016 Oct; 86(2): 205-10. DOI: 10.1016/j.diagmicrobio.2016.07.01527489118
  27. 27. Kan WC, Huang YT, Wu VC, Shiao CC. Predictive Ability of Procalcitonin for Acute Kidney Injury: A Narrative Review Focusing on the Interference of Infection. Int J Mol Sci. 2021 Jun 27;22(13):6903. DOI: 10.3390/ijms22136903826824934199069
  28. 28. Dong R, Wan B, Lin S, Wang M, Huang J, Wu Y, et al. Procalcitonin and Liver Disease: A Literature Review. J Clin Transl Hepatol. 2019 Mar 28;7(1):51-5. DOI: 10.14218/JCTH.2018.00012644164830944820
  29. 29. Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, et al. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol. 2006 May; 18(5): 525-30. DOI: 10.1097/00042737-200605000-0001216607149
  30. 30. McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. 2021 Mar;17(3):145-7. DOI: 10.1038/s41584-020-00571-1786361533547426
  31. 31. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014 Apr;6(4):748-73. DOI: 10.1039/C3MT00347G24549403
  32. 32. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. Front Immunol. 2019 Feb 1;10:119. DOI: 10.3389/fimmu.2019.00119636726230774631
  33. 33. Pál K, Molnar AA, Huțanu A, Szederjesi J, Branea I, Timár Á, et al. Inflammatory Biomarkers Associated with In-Hospital Mortality in Critical COVID-19 Patients. Int J Mol Sci. 2022 Sep;23(18):10423. DOI: 10.3390/ijms231810423949935236142336
  34. 34. Carubbi F, Salvati L, Alunno A, Maggi F, Borghi E, Mariani R, et al. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Sci Rep 2021 Mar;11(1):4863. DOI: 10.1038/s41598-021-83831-8792138633649408
  35. 35. Ghio AJ, Ford ES, Kennedy TP, Hoidal JR. The association between serum ferritin and uric acid in humans. Free Radic Res. 2005 Mar;39(3):337-42. DOI: 10.1080/1071576040002608815788238
  36. 36. Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, et al. Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study. BMC Pulm Med. 2021 Mar 20;21(1):96. DOI: 10.1183/13993003.congress-2021. PA3663
DOI: https://doi.org/10.2478/rrlm-2023-0004 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 35 - 42
Submitted on: Oct 26, 2022
|
Accepted on: Dec 27, 2022
|
Published on: Feb 8, 2023
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2023 Daniela Rădulescu, Cristiana David, Elena Cuiban, Flavia Liliana Turcu, Larisa Florina Feier, Simona Daniela Onofrei, Ileana Adela Văcăroiu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.